niacinamide has been researched along with Carcinoma, Squamous Cell of Head and Neck in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The dose escalation, confirmation, and expansion results support the dosing of merestinib at 120 mg once daily, based on acceptable exposure and safety at this dose." | 2.90 | First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. ( Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W, 2019) |
| "Sorafenib was administered orally at 400 mg bid on a continuous basis." | 2.82 | Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. ( Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M, 2016) |
| "Radioresistance is a common feature of head and neck squamous cell carcinoma (HNSCC)." | 1.46 | Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. ( Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W, 2017) |
| "In head and neck squamous cell carcinoma (HNSCC), the role of sprouty2 in tumorigenesis and clinical implication remains elusive." | 1.42 | Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL, 2015) |
| "Head and neck squamous cell carcinoma (HNSCC) is an aggressive epithelial malignancy." | 1.42 | Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. ( Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 2 |
| Jing, Y | 1 |
| Wang, S | 1 |
| Wu, Y | 1 |
| Sun, Y | 1 |
| Zhuang, J | 1 |
| Huang, X | 1 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Song, Y | 1 |
| Hu, Q | 1 |
| Ni, Y | 1 |
| He, AR | 1 |
| Cohen, RB | 1 |
| Denlinger, CS | 1 |
| Sama, A | 1 |
| Birnbaum, A | 1 |
| Hwang, J | 1 |
| Sato, T | 1 |
| Lewis, N | 1 |
| Mynderse, M | 1 |
| Niland, M | 1 |
| Giles, J | 1 |
| Wallin, J | 1 |
| Moser, B | 1 |
| Walgren, R | 1 |
| Plimack, ER | 1 |
| Laban, S | 1 |
| Steinmeister, L | 1 |
| Gleißner, L | 1 |
| Grob, TJ | 1 |
| Grénman, R | 1 |
| Petersen, C | 1 |
| Gal, A | 1 |
| Knecht, R | 1 |
| Dikomey, E | 1 |
| Kriegs, M | 1 |
| Bhatt, VR | 1 |
| Ganti, AK | 1 |
| Lalami, Y | 1 |
| Garcia, C | 1 |
| Flamen, P | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Awada, A | 1 |
| Lin, CL | 1 |
| Chiang, WF | 1 |
| Tung, CL | 1 |
| Hsieh, JL | 1 |
| Hsiao, JR | 1 |
| Huang, WT | 1 |
| Feng, LY | 1 |
| Chang, CH | 1 |
| Liu, SY | 1 |
| Tsao, CJ | 1 |
| Feng, YH | 1 |
| Aderhold, C | 1 |
| Faber, A | 1 |
| Umbreit, C | 1 |
| Birk, R | 1 |
| Weiss, C | 1 |
| Sommer, JU | 1 |
| Hörmann, K | 1 |
| Schultz, JD | 1 |
| Affolter, A | 1 |
| Samosny, G | 1 |
| Heimes, AS | 1 |
| Schneider, J | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Sommer, K | 1 |
| Jensen, A | 1 |
| Mayer, A | 1 |
| Brenner, W | 1 |
| Mann, WJ | 1 |
| Brieger, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of LY2801653 in Patients With Advanced Cancer[NCT01285037] | Phase 1 | 190 participants (Actual) | Interventional | 2009-09-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell | 2019 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head a | 2016 |
6 other studies available for niacinamide and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Identification of Biological Functions and Prognostic Value of NNMT in Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Niacinamide; Nicotinamid | 2022 |
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide | 2013 |
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Pheny | 2014 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulati | 2015 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulati | 2015 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combin | 2017 |